Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021 07:15 ET
|
Vera Therapeutics
Company makes ongoing progress in several areas evaluating atacicept, its lead product candidate Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a...
Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021
November 04, 2021 16:05 ET
|
Vera Therapeutics
Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 (Gd-IgA1) in a dose-dependent...
Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting
October 13, 2021 07:30 ET
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological...
Vera Therapeutics Hosting Key Opinion Leader Webinar on IgA Nephropathy
September 09, 2021 07:30 ET
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological...
Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 16, 2021 07:30 ET
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological...
Vera Therapeutics Appoints Sean Grant as Chief Financial Officer
July 14, 2021 07:30 ET
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
June 24, 2021 07:15 ET
|
Vera Therapeutics
Completed an initial public offering with net proceeds, including the exercise of the underwriters’ option in full, of approximately $48.4 million in May 2021 - - -Expanded the management team to...
Vera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 27, 2021 16:05 ET
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Pricing of Initial Public Offering
May 13, 2021 20:52 ET
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative...